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Abstract 
Parkinson’s disease is a common neurodegenerative disorder characterized by tremors 
and motors deficits, caused by the death of dopaminergic neurons and the resulting 
dopamine depletion in the brain. Examination of the substantia nigra of the brains of 
Parkinson’s patients reveals abnormal intraneuronal deposition of fibrillar aggregates of 
the protein α-synuclein. While Parkinson’s disease is generally idiopathic in origin, 
several mutations in α-synuclein have been shown to increase the likelihood of the 
disease. This further implicates α-synuclein in the pathogenesis of Parkinson’s disease. 
This report focuses on wild type α-synuclein. A 31-residue peptide corresponding to 
residues 6-36 of the N-terminus of a-synuclein was synthesized, purified, and its 
conformation examined using circular dichroism spectroscopy.  The peptide showed 
conformational behavior that is similar to what has been found for this region in the full-
length protein. Thus, the peptide can be used as a model system for the N-terminal region 
of α-synuclein. In future work, this peptide model and its A30P mutant counterpart can 
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Parkinson’s Disease and Lewy Bodies 
 Parkinson’s disease is a devastating neurological condition causing uncontrollable 
shaking, muscle rigidity, and slowed movement. First described by James Parkinson in 
1817, Parkinson’s disease is the second most common neurodegenerative condition after 
Alzheimer’s disease.1 Until recently, Parkinson’s disease had been viewed only as a 
movement disorder, but as of 2012, the clinical spectrum has come to include early non-
motor features.2 In the pre-motor phase, usually before clinical diagnosis, common 
symptoms include reduced sense of smell, rapid-eye-movement behavior disorder, 
depression, and constipation.3 Later on, there is the characteristic debilitating motor 
impairment with tremors, difficulty initiating movement, and postural instability.4 
Cognitive decline and dementia is common in advanced disease.5  
 
a)             b)  
Figure 1: The structures of a) dopamine and b) Levodopa. 
 
Parkinson’s disease is a consequence of the death of dopaminergic neurons in the 
substantia nigra, leading to reduced production of the neurotransmitter dopamine (Figure 
1a).5 Currently, there is no treatment that can slow, stop, or reverse this cell death.6 The 
only therapeutic option is symptomatic treatment.6 The most common treatment is 









cross the blood-brain barrier to replace the dopamine that the damaged neurons can no 
longer produce.5 A limitation of this drug is that dopaminergic neurons in the substantia 
nigra are needed to convert the Levadopa to dopamine.7 When too many neurons have 
died, the drug loses its efficacy.  
When the substantia nigra of Parkinson’s patients are examined, these neurons are 
found to contain Lewy bodies8 - intracytoplasmic inclusions made up of fibrillar 
aggregates of the protein α-synuclein.8 As point mutations (A30P, E46K, A53T) and over 
expression of the gene coding for α-synuclein have been linked to Parkinson’s disease, it 
is clear that this protein is important to the pathogenesis of the disease.9,10 This work will 
establish the basis to characterize the chemical changes of the A30P mutation by 




 For many proteins, such as hemoglobin, collagen, and actin, assembly into 
oligomers of a defined size is necessary for proper protein function.11 For other proteins, 
unnatural assembly, called aggregation, spells disaster. A schematic of the possible 
pathways of aggregation is shown below (Figure 2).  
 
 
Figure 2: Schematic of the possible pathways of protein aggregation.12 
 
Aggregation is a generic property of peptides and proteins.13 It is generally an 
entropy driven process, believed to be a result of the water molecules released from the 
hydration shell upon assembly of the aggregate, due to a decrease in surface area.11  
There are more than 40 human diseases14 caused by the aggregation of at least 20 
different proteins or peptides.15 For most of these species, aggregation is a consequence 
of misfolding of the protein or production of fragments of the protein that are unable to 
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fold properly.13 In this type of aggregation, the proteins form amyloid fibrils 
characterized by extensive β-sheet structure, with the β-strands perpendicular to the fibril 
axis.14 This structure is called a cross-β fibril. These fibrils accumulate to form insoluble 
amyloid plaques in the affected organ, such as the pancreas in type II diabetes, the heart, 
liver, and kidney in various forms of systemic amyloidosis, and the brain in 
neurodegenerative disorders.15 These deposits can be extracellular, cytoplasmic, or 
nuclear.16 Specific proteins have been identified in several of the most common 
neurodegenerative disorders, including amyloid-β (Alzheimer’s disease), polyglutamine 
(Huntington’s disease), prion proteins (prion diseases), and α-synuclein (Parkinson’s 
disease).11 These proteins have very little in common in their primary sequences, but they 
are very similar in their ability to undergo the conformational change to a cross-β fibril 
aggregated structure.16  
 Dimers and trimers of amyloid-β, aggregates of prion proteins, and protofibrils of 
α-synuclein have been shown to be toxic to cells in vitro.16 There are competing theories 
about the mechanism of toxicity. One theory is that the toxicity is caused by exposure of 
residues, typically buried in the interior of the protein in the correctly folded native state, 
that become exposed to and damage the cellular components in the diseased state.13 
Another theory is that early amyloid aggregates organize into doughnut shaped 
assemblies, which form pores in the cellular membranes and disrupt homeostasis.13 
Whatever the mechanism, we can inhibit the toxicity by inhibiting the conformational 
shift to amyloid cross β-sheet structure. This can be accomplished by stabilizing the 
native structure or by destabilizing the amyloid structure. 
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α-Synuclein Function and Structure 
 α-Synuclein is estimated to account for around 1% of brain protein.17 Its normal 
function is not fully understood, but postulated actions include the refilling and 
trafficking of synaptic vesicles,18  fatty acid binding,19 and regulation of dopamine.20 It is 
not essential to the neurotransmitter release processes, but is thought to contribute to the 
long-term maintenance of nerve terminal function.21  
α-Synuclein is a natively unstructured 140 amino acid protein lacking both 
cysteine and tryptophan,22 and containing an imperfectly repeated 11-residue consensus 
sequence with a highly conserved KTKEGV motif and linker residues.23 Its sequence is 
below (Figure 3).  
 
 
Figure 3: The sequence of human α-synuclein, split into its three domains. The 
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α-Synuclein is made up of three domains with very different properties (Figure 
4). The amino terminal domain (residues 1-65) is highly conserved among different 
species.24 As shown below, the first five of the six repeats are in the amino terminal 
repeat domain. NMR studies have shown that, upon membrane binding, this region 
adopts an α-helical conformation consisting of two helices interrupted by a short break 
around residues 43-44.25	  
 
 
Figure 4: Human α-synuclein domains. The conserved motif is shown as the darkest 
grey boxes. 
 
 The central domain (residues 66-95) is known historically as the non-Aβ 
component of plaque (NAC) because of its inclusion in the characteristic plaques of 
Alzheimer’s disease.26 It has been hypothesized to be responsible for the conformational 
change from random coil to β-sheet necessary to form fibrils.27 The carboxy terminal 
domain (residues 96-140) has a strong negative charge, and is highly variable between 
species.28 It has no recognized structural elements.24 
 Experiments have shown that α-synuclein can adopt a number of conformations 
in vitro, though little is known about the states of the protein in vivo.10 These 
conformations may be stabilized by long-range interactions.29 From studies purifying α-
synuclein from E. coli, we know that it exists as an unfolded monomer under native 
conditions,30 but there are also a number of different conformations that have been 
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implicated in the pathogenesis of Parkinson’s disease, including oligomers, protofibrils, 
and fibrils. It is possible that, naturally, α-synuclein exists in equilibrium between these 
different conformational and oligomeric states. Of these states, partially folded and 
soluble oligomers have exhibited neurotoxicity in vitro, whereas insoluble aggregates and 
fibrils are hypothesized to be neuroprotective, since their formation from the smaller 
aggregates has lowered toxicity.22 These conformational changes are likely to be 
important in the pathogenesis of Parkinson’s disease and Lewy body formation. 
 
 
Figure 5: The α-synuclein aggregation process from monomers to fibrillar aggregates.31 
  
The currently accepted model of α-synuclein aggregation is shown in Figure 5. 
These fibrillar aggregates are the main component of Lewy bodies.32 If the hypotheses 
about the toxicity of the intermediates and the neuroprotective nature of the insoluble 
aggregates are true, then the formation of Lewy bodies may be an attempt to sequester the 






Stabilizing α-Helices and Salt Bridges 
 The stability of an α-helix depends on its amino acid composition. The likelihood 
of an amino acid to be in an α-helix can be estimated based on the compositions of 
known helices, or determined experimentally using thermodynamic studies. Values based 
on both methods are shown below (Table 1). 
 




Glu 1.51 -0.27 
Met 1.45 -0.50 
Ala 1.42 -0.77 
Leu 1.21 -0.62 
Lys 1.16 -0.65 
Phe 1.13 -0.41 
Gln 1.11 -0.33 
Trp 1.08 -0.45 
Ile 1.08 -0.23 
Val 1.06 -0.14 
Asp 1.01 -0.15 
His 1.00 -0.06 
Arg 0.98 -0.68 
Thr 0.83 -0.11 
Ser 0.77 -0.35 
Cys 0.70 -0.23 
Tyr 0.69 -0.17 
Asn 0.67 -0.07 
Gly 0.57 0.00 
Pro 0.57 ~3 
a. Pα is a measure of the frequency of each residue in naturally occurring α-helices.
33 
b. ΔΔGα is the difference in free energy of helix formation of each residue compared to 
that of glycine.34 
 
From these values, we see that it is favorable for alanine to be in a helix, and unfavorable 
for proline to be in a helix. Though it is often a helix breaker, and despite its high ΔΔG 
value, proline is sometimes found in α-helices. When this occurs, the ring of the proline 
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pushes away from the preceding turn of the α-helix by about one angstrom, producing a 
bend of about 30° in the helix axis, and breaking the hydrogen bond of the following 
amino acid.35 This kink is shown in Figure 6. 
 
 
Figure 6: An α-helix containing a proline, showing the missing hydrogen bond and the 
30° kink.35 
 
 The charged amino acids glutamine and lysine are commonly found in α-helices. 
If appropriately spaced, these amino acids can stabilize an α-helix by forming a salt 
bridge. When two oppositely charged amino acids are four residues apart, their side 
chains are optimally aligned for an ionic interaction. Since the helix has a dipole that is 
positive at the N terminus and negative at the C terminus resulting from the polarity of 
the carbonyls, the electrostatic effects of this ionic interaction are favorable if the 




Figure 7: Helical wheel projection of residues 6-36 of α-synuclein, showing the salt 
bridge between E28 and K32. 
 
We can examine the putative α-helix that would be formed by residues 6-36 of α-
synuclein by plotting the peptide on a helical wheel projection (Figure 7). From this 
projection, we can see that there is likely to be a salt bridge between E28 and K32, and 
that this interaction is in the correct alignment with the helix dipole. This salt bridge may 
be broken by the A30P mutation, as the residues will be farther apart on a bent helix. 
From this, we can see how disruptive this mutation will be on the stability of the α-helix 
of the N-terminal repeat region. 
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Ubiquitination of α-Synuclein 
 α-Synuclein can be modified by several post-translational modifications including 
serine and tyrosine phosphorylation, nitration, enzymatic crosslinking, C-terminal 
truncation, and ubiquitination.37 The only one affecting the N-terminal repeat domain is 
ubiquitination.  
 Ubiquitin is a 76-residue protein which is attached to another protein by the 
sequential action of three enzymes.38 This process is summarized in Figure 8. 
 
 
Figure 8: In the first step, the C-terminal glycine residue of ubiquitin is activated by an 
ATP-dependent specific activating enzyme (E1), where ubiqutin forms a 
thiolester linkage to a cysteine residue of E1. In step two, the activated 
ubiquitin is then transferred to a cysteine residue of a ubiquitin-carrier protein 
(E2). In the third step, a ubiquitin-protein ligase (E3) catalyzes the linkage of 











The two proteins are attached by an isopeptide bond between the C-terminus of ubiquitin 
and the ε-amino group of the substrate’s lysine residue (Figure 9).  
 
 
Figure 9: The isopeptide bond (bolded) between ubiquitin’s C-terminal G76 to one of the 
substrate’s lysine residues. 
 
Ubiquitin has seven lysine residues, all of which can be ubiquitinated, forming 
polyubiquitin chains, which regulate different processes, such as DNA repair, and protein 
degradation by the autophagy and proteasome systems.40 Alternately, monoubiquitination 
regulates the activity of proteins located at membranes, and can target them for 
degradation in the lysosome.41 
 α-Synuclein is lysine rich, containing 15 lysine residues, and is modified at 
different sites by three different ubiquitin-protein ligases: parkin, UCH-L1, and SIAH.37 
Mutations in parkin and UCH-L1 have been linked to familial Parkinson’s disease, and 
Parkinson’s disease susceptibility, respectively, indicating that ubiquitination is an 
important process in preventing the disease.37 Additionally, ubiquitin is a common 
inclusion in the core of Lewy bodies, but absent from the periphery, which implicates the 
ubiquitination of α-synuclein in the early stages of Lewy body formation.42  
The cellular basis for α-synuclein ubiquitination is not well understood, especially 












process.39 Two popular theories are that the modification is an attempt to (1) unfold or 
degrade misfolded α-synuclein, or (2) block interactions of inappropriately exposed 
residues.43 Whatever the reason, this modification backfires, as ubiquitinated α-synuclein 
inhibits the proteasome system by partly entering the proteasome and causing steric 
occlusion.39 Alone, proteasome inhibition does not generally cause cell toxicity, but it has 
been shown to strongly enhance the toxicity of α-synuclein species.39 In summary, 
ubiquitin plays a supporting role in the pathogenesis of Parkinson’s disease, as a lack of 
ubiquitination can increase susceptibility to contract the disease, but proper ubiquitination 
can increase the toxicity of the α-synuclein oligomeric species.  
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The A30P Mutation 
In 1998, a missense mutation was discovered in a German family that passed 
down early onset familial Parkinson’s disease as an autosomal dominant trait – the 
replacement of an alanine at residue 30 with a proline (A30P).44 The amino acids alanine 
and proline (Figure 10) have very different chemical properties. 	  
 
a)                 b)  
 
Figure 10: Structures of a) alanine and b) proline. 
 
 
Alanine is small, nonpolar, and slightly hydrophobic. Since its side chain is so small, 
there is very little steric hindrance, and therefore it can be a part of many conformations. 
Proline is also a small amino acid, but it is unique in having a secondary rather than a 
primary amine. When proline is in a peptide chain, it has no hydrogen available for 
hydrogen bonding. This means that proline creates kinks in helices, and is likely to be 
found in tight turns. The effects of this mutation on secondary structure have been studied 
for full-length α-synuclein. 
Circular dichroism45 and FTIR46 data have shown that under physiological 
conditions, A30P α-synuclein has the same natively unfolded conformation as wild type 
α-synuclein.45 Additionally, similar to wild type α-synuclein, the mutant undergoes a 
reversible transformation to a partially folded state under acidic or heated conditions.47 










structure of the protein. The α-helicity of mutant α-synuclein has been studied 
experimentally by NMR α-carbon chemical shifts48,49 and predicted computationally by 
the heirarchical neural network method50, resulting in agreement that the helical 
propensity of residues 18-31 present in wild type α-synuclein is absent in the mutant. 
Specifically, the helicity is most perturbed at E28.49 As was stated earlier, E28 likely 
forms a salt bridge with K32. Disrupted helicity at E28 will also disrupt the salt bridge, 
further affecting the stability of the helix in this region. The same compuations predict 
that the mutant is more likely to form β-structure than wild type α-synuclein.50 Circular 
dichroism data confirms this prediction.51 Additionally, FRET data suggests that proline 
significantly affects the three-dimensional conformation of α-synuclein, bringing the N 
and C termini closer together than in the wild-type protein.52 NMR residual dipolar 
couplings and paramagnetic relaxation enhancement studies corroborate that the mutation 
perturbs the native conformation, and makes the backbone more flexible.29 These 
secondary and tertiary structure effects will affect the behavior of A30P α-synuclein in its 
membrane binding and aggregation. 
There has been conflicting evidence on the effects of the A30P mutation on α-
synuclein lipid interactions. Certain studies have shown a complete lack of membrane 
binding by the mutant.53 This result may be caused not by the mutation, but by the biotin 
used in the assay, which has since been shown to eliminate α-synuclein membrane 
binding.54 Other studies have shown that the mutation has no effect on protein binding to 
the membranes of intact cells.52 Others have shown decreased or defective binding to 
phospholipid vesicles.49, 54, 55 Additionally, circular dichrosim has shown that the A30P 
mutant does not undergo the normal transition from random coil to α-helix in the 
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presence of lipids.55 The lack of lipid membrane binding may be imporant for the 
pathogenesis of Parkinson’s disease, as there will be a higher population of free α-
synuclein, which may increase the kinetics of aggregation. 
 We know that when α-synuclein aggregates, it undergoes a secondary structure 
change from its initial random coil formation to an anti-parallel β-sheet.46  Therefore, the 
greater propensity for β-sheets of the A30P mutant is expected to affect its aggregation. 
SDS-PAGE, thioflavine-S staining, electron microscopy and circular dichroism studies 
all show that the mutant protein aggregates at a higher rate than the wild type.51, 46 
Conway et al. clarify that while the soluble A30P monmer forms oligomers more rapidly 
than the wild type, its fibrils form more slowly.56 This means that the mutant α-
synuclein’s aggregation kinetics favor the prefibrillar intermediate. Aggregation is also 
enhanced by the increased flexiblity of mutant α-synuclein, as it can more easily 
overcome the barrier for self association.29 Electron micrographs show that the mature 
fibrils formed from the mutant and wild type α-synuclein are indistinguishable.57  
 In summary, the studies comparing wild type and A30P α-synuclein have found 
that the mutant’s decreased propensity for α-helical structure and increased likelihood for 
β-sheet structure lead to decreased lipid binding, increased oligomerization, and 
decreased fibrillization, but do not seem to affect the mechanism of aggregation. All of 
these studies have been done on the full-length protein. The effects of the mutation can be 
determined more specifically and definitively if we examine only the region surrounding 
the mutation.  
This work examines the secondary structure of a small synthetic fragment of 
residues 6-36 of wild type α-synuclein with circular dichroism spectroscopy under 
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varying conditions. This fragment was synthesized using solid phase peptide synthesis. In 
future work, these tests can be repeated for the same residues of the mutant protein to 
elucidate the changes caused by the mutation. These results will further our 
understanding of the conformational changes inherent to the pathogenesis of Parkinson’s 
disease, and will be valuable to those working to develop therapies that interrupt the 
aggregation process.  
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Solid Phase Peptide Synthesis 
Developed in the 1960’s, solid phase peptide synthesis is a process for making 
peptides, commonly used when the protein cannot be expressed with bacteria. In this 
novel approach, the C-terminal amino acid is anchored to an insoluble resin bead (Figure 
11), which acts as a solid support for the growing peptide chain.58, 59, 60 
 
 
Figure 11: Resin with Fmoc protected Rink linker. The circled P is polystyrene.  
 
Amino acids are added stepwise to the free end of the growing polypeptide chain. The 
resin bead prevents the chain from passing through a filter during the synthesis, allowing 
for easy separation of the chain from the solvent and reagents. This allows one to run the 
synthesis with excess reagents, producing higher yields after each step than traditional 
organic synthesis, as the excess drives reactions to completion. Additionally, since the 
polypeptide chain is purified after synthesis rather than between each addition of amino 
acid, solid phase peptide synthesis minimizes loss of product during purification.  
In solid phase peptide synthesis, the peptide is bound to the resin by the C-
terminus. During the synthesis, new amino acids are attached to the N-terminal amino 










carboxylic acid group of the new amino acid. If the side chain of an amino acid is able to 
react, it must be protected to prevent any undesired reactions. Additionally, the amine of 
the amino acid being added must be protected to prevent it from reacting with itself. 
Therefore we need a “temporary” protecting group for the α-amino groups that can be 
removed during each coupling cycle, and a “semi-permanent” one to protect the side 
chains that will be removed only after the synthesis is complete.  
In our synthesis, we use fluorenyl-methoxy-carbonyl (Fmoc), for the “temporary” 
protecting group, and tert-butoxycarbonyl (t-Boc), for the “semi-permanent” protecting 
group (Figure 12).  
 
a)           b)  
 
Figure 12: Structure of a) Fmoc and b) t-Boc protecting groups.  
 
These two are orthogonal protecting groups, as Fmoc is labile in base and t-Boc is labile 
in acid. The Fmoc group can be removed in the mild base piperidine. The t-Boc groups 












Figure 13 outlines the key steps of solid phase peptide synthesis. Details for each 
step will follow. 
 
 








































































First the Fmoc protecting group is removed under basic conditions using 
piperidine to reveal a free amine at the N-terminus of the peptide chain (Figure 14).  
 
 





































CO2       +
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Then the new amino acid must be activated using diisopropylcarbodimide (DIC) 
and 1-hydroxybenzotriazole (HOBt), which converts the carboxylic acid into an ester. 
This ester then undergoes nucleophilic attack from the nitrogen of the free amino group, 
forming a peptide bond between the new amino acid and the growing peptide chain 
(Figure 15).  
 
 








































































In every coupling step, fewer than 2% of the peptide chains do not successfully 
react with the new amino acid. As these chains have been deprotected and have a free 
amino group, they are reactive. They may couple with other amino acids in later steps of 
the synthesis, creating unwanted peptides with deletions. To avoid this, we can cap the 
free amino groups by acetylating them using acetic anhydryde (Figure 16).  
 
 


























Once the synthesis is complete, the side chain protecting groups can be removed 
in the same step as cleaving the peptide from the resin solid support using TFA (Figure 
17).  
 
a)      b)  
Figure 17: a) cleavage of peptide from rink linker and b) deprotection of t-Boc group 
using strong acid. 
 
The crude peptide can then be purified using high pressure liquid chromatography and 









































Reversed Phase High Pressure Liquid Chromatography (HPLC)61 
 Chromatographic separations are based on the interactions of different 
compounds with a liquid mobile phase moving through the solid stationary phase of a 
column. HPLC is named for the high-pressure system that pushes the mobile phase 
through the column. A reversed phase system separates components based on their 
hydrophobic nature with a hydrophobic stationary phase and a polar mobile phase. In this 
research the separation is done on a C18 column, which has silica derivatized with 
hydrocarbon chains that average 18 carbons in length as the stationary phase. The mobile 
phase is a mixture of acetonitrile and water, the composition of which changes over time 
according to a linear gradient. As we increase the amount of acetonitrile, we in turn 
decrease the polarity of the mobile phase. In the column, each component of our crude 
peptide mixture is in equilibrium between adsorption on the solid phase surface and 
dissolution in the mobile phase. Since this equilibrium is based on hydrophobic 
interactions, as we increase the concentration of acetonitrile in the mobile phase, we shift 
the equilibrium to dissolution. The equilibria for the different peptides will shift at 
different rates, so they will have different rates of movement through the column and 
elute at separate times. We can monitor this process with UV absorbance measurements 
of the eluant.  
 In practice, the difficulty of HPLC is in optimizing the gradient, or solvent 
program. Changing the concentrations of the mobile phase and the rate at which they 
change will affect when components elute. An optimized system has the desired product 
elute from the column quickly and with high purity. Once a system is optimized, it can be 
used to purify the desired peptide. 
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Circular Dichroism Spectroscopy 
 The secondary structure of a peptide is determined by the dihedral angles (Figure 
18) of its backbone, and certain hydrogen bonds.  
 
 
Figure 18: The dihedral angles of a peptide backbone. The φ angle is along the α-carbon 
to nitrogen bond, and the ϕ angle is along the α-carbon to carbonyl bond. 
 
For example, the α-helix has dihedral angles φ=60° and ϕ=45°, and hydrogen bonds from 
the carbonyl group of the ith residue to the NH of the i+4th residue. The β-sheet has 
dihedral angles φ=130° and ϕ=20°, and hydrogen bonds between β-strands, which can be 
arranged parallel or antiparallel to each other.62 These structures are shown in Figure 19. 
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 A beam of light has associated time dependent electric and magnetic fields, and 
can be polarized differently using suitable prisms and filters.64 For circular dichroism 
spectroscopy, we use circularly polarized light, which is made up of clockwise (ER) and 
counterclockwise (EL) components. When asymmetric molecules interact with circularly 
polarized light, they absorb the two components differently, resulting in ER and EL 
vectors of different intensities that sum to an ellipse.64 This light is said to be elliptically 
polarized. For a detailed and animated explanation of circularly polarized light and its 
interaction with matter, see Szilágyi’s website.65  
  
a)            b)  
Figure 20: Circular dichroism spectra of a) pure and b) composite secondary structure.66 
 
In a circular dichroism spectrometer, the chirality of bonds can be elucidated 
based on the absorbance of the two components of circularly polarized light, and the 
resulting ellipticity, defined as the angle whose tangent is the ratio of the minor to the 
major axis of the ellipse.64 For proteins, we can see the amide of a peptide bond at 
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wavelengths below 250 nm.62 Experimental data have produced model curves of the 
ellipticities at different wavelengths for each secondary structure. These curves are shown 
in Figure 20a. Additionally, it is possible to determine the secondary structure 
composition of a protein by adding the standard curves to fit the experimental curve, as 





Results and Discussion 
 
In the first phase of this project, a peptide following the sequence of residues 6-36 
of α-synuclein was synthesized using solid phase peptide synthesis. After synthesis, the 
crude peptide was analyzed using reversed phase high performance liquid 
chromatography (HPLC). The crude peptide displayed three peaks (Figure 21). 
 
Figure 21: Absorbance at 225 nm of eluant from the analytical HPLC of crude peptide. 
 
Note that the large peak at the end of the separation is due to a wash of the column with 
acetonitrile. The peptide isolated from each peak was analyzed using MALDI-TOF mass 
spectroscopy. The spectra for peaks A, B, and C are shown in appendices 1, 2, and 3 
respectively. The calculated mass for residues 6-36 of α-synuclein is 3042 Da, so it is 
expected to have an [M+H] peak at 3043 M/Z. The mass spectra show that this peptide is 
the major component of peak A in high purity. 
A	  	  	  B	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  C	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 The HPLC analysis was then scaled up to preparative scale, and optimized to 
baseline resolve peaks A and B, and minimize the time of each run (Figure 22). The 
optimization process is the key to a good purification. Baseline resolution is necessary to 
ensure high purity. Short run time is optimal for two reasons. First, it reduces cost in 
labor and materials. Secondly, shorter retention times yield narrower peaks, and therefore 
more concentrated eluant, which makes isolation of the pure peptide easier. 
 
 
Figure 22: Absorbance at 225 nm of eluant from the preparative HPLC of crude peptide. 
 
As we can see from the new absorbance spectra of the preparative eluant, the new solvent 
profile has allowed for narrower, resolved peaks, and has shortened the retention time of 
	  	  A	  	  B	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peak A from 30 minutes to 21 minutes. Run time could not be shortened further, as it 
interfered with the resolution of the two peaks.  
The peptide purified by HPLC was isolated from solution, and then examined 
using circular dichroism spectroscopy. Though residues 6-36 of α-synuclein form an α-
helix upon membrane binding in the full protein, a fragment of these residues may act 
differently. The rules governing small peptides’ secondary structures are different from 
those of large proteins.68 For example, if a secondary structure is stabilized by long-range 
interactions, the absence of these distant residues means the protein may not fold 
correctly. Since α-synuclein is intrinsically unstructured, we do not expect much tertiary 
structure or long-range interactions. Based on this, we expect that a fragment of α-
synuclein will act as a model of its respective region of the full protein. Additionally, 
peptides that are too short will not adopt secondary structure, regardless of any other 
factor, because their conformational change is not entropically favorable. By synthesizing 
a 31-residue peptide, we have avoided this issue. If our peptide does undergo the 
expected conformational shift from random coil to α-helix upon membrane interactions, 
then we will have confirmed that it is a good model system for the region of α-synuclein 
surrounding the A30P mutation. 
2-(4-Morpholino)-ethane sulfonic acid (MES) buffer is commonly used in peptide 
analysis since it has a pKa of 6.15 at 20°C and minimal change at other temperatures, and 
therefore a good buffering capacity at physiological pH. It is also chemically and 
enzymatically stable, highly water soluble, and has minimal absorption in the UV range. 
All these characteristics combined make it a good buffer for examining the CD spectra of 
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peptides.69 In 10 mM MES buffer in water at pH 7, the peptide showed random coil 
secondary structure (Figure 23).  
 
 
Figure 23: Circular dichroism spectra of residues 6-36 of α-synuclein in pH 7 10 mM 
MES buffer in water. The peptide had random coil secondary structure at 
room and body temperatures (25°C and 37°C respectively). 
 
 2,2,2-Trifluoroethanol (TFE) solutions can mimic membrane environments by 
minimizing peptide-water interactions and stabilizing hydrogen bonds between the amino 
acids.70,71 It can be thought of as a secondary structure enhancer. In 10 mM MES buffer 




























Figure 24: Circular dichroism spectra of residues 6-36 of α-synuclein in pH 7 10 mM 
MES buffer in 50% v/v TFE in water. The peptide had α-helical secondary 
structure at all scanned temperature, with slight denaturation as temperature 
increased. 
 
These studies show that the peptide of residue 6-36 of α-synuclein acts similarly 
to the corresponding residues in the full-length protein. The peptide has random coil 
secondary structure natively, but adopts an α-helical structure in a membrane mimetic 
solution. This confirms that we will be able to use this peptide as a model system for the 




























 Now that we have confirmed that a small peptide fragment containing residues 6-
36 of α-synuclein acts as a model of its region in the full protein, we can use it to probe 
the chemical changes caused by the A30P mutation. This will be a two-step process.  
In step one, we will further characterize the secondary structure of the wild type 
peptide using CD spectroscopy and varying temperature, pH, and buffer environments. 
So far, we have examined the protein at 25°C and 37°C. We can study the stability of the 
helix in the TFE, MES buffer by doing temperature denaturation studies. By examining 
the peptide at higher temperatures, we can determine the thermodynamics of α-synuclein 
folding around residue 30. We have also only studied the peptide at pH 7. Future studies 
will examine the peptide at other pH values. By changing the pH, we will change which 
amino acid side chains are protonated or deprotonated. This can change the nature of the 
E28-K32 salt bridge and any other ionic interactions. These studies will show to what 
extent ionic interactions are necessary to the stability of the α-helix. Lastly, we have 
studied the secondary structure shift from a 0% to a 50% TFE buffer environment. We 
can examine this shift further by performing a TFE titration on our buffer environment. 
In this way, we can determine how much TFE is required to promote the conformational 
change and determine how hydrophobic interactions influence this change. 
In step two, we will characterize the chemistry of the A30P mutation. By 
repeating all studies from step one on the mutant peptide, we can determine how the 
mutation changes the secondary structure of the peptide, and α-synuclein as a whole. A 
comparison of the data collected in the two steps will further our understanding of α-
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synuclein’s conformational changes, and can be used by those working to develop 






Solid Phase Peptide Synthesis 
 Synthesis was carried out using 2 g of Rink amide resin as the solid support. 
 
Deprotection of the N-Terminal Amino Acid 
To remove the fluoroenylmethyloxycarbonyl (Fmoc) protecting group from the 
N-terminal amino acid on the peptide chain, the resin was mixed for 2 minutes with 15 
mL of 25% piperidine in dimethylformamide (DMF), and then for 15 minutes with 15 
mL of the same solution. The resin was then washed four times for 1 minute each with 15 
mL of DMF. The deprotected amino group was then ready for coupling to another amino 
acid. 
 
Amino Acid Coupling 
To add a new amino acid to the growing peptide chain, first 2.7 mmol of the 
amino acid was dissolved in 4 mL of DMF, 4.5 mL of 0.65 M hydroxybenzotriazole in 
DMF, and 4.5 mL of 0.65 M N,N′-diisopropylcarbodiimide in DMF. This solution was 
then added to the resin and mixed for 60 minutes. The resin was then washed three times 
with 15 mL of DMF. This whole process was repeated twice with each amino acid to 





Acetylation of Unreacted Peptide Chains 
 After a coupling, the free amino groups on the unreacted peptide chains were 
capped by acetylation. To cap, the resin was mixed for 12 minutes with 15mL of 0.3 M 
acetic anhydride in DMF. The resin was then washed 4 times with 15 mL of DMF.  
 
The deprotection, coupling, and capping were repeated until the chain was complete. This 




The progress of the synthesis was monitored by determining the substitution level 
of Fmoc on the peptide. This was done by removing these protecting groups from the 
chain and determining their concentration in solution. A drastic change in substitution 
level is indicative of poor yield in a step of the synthesis. A 5-10 mg sample of the resin-
bound peptide was washed with dichloromethane, and then dried under vacuum. This 
sample was then dissolved in 1 mL of 20% piperidine in DMF and mixed for 20-25 
minutes to remove the Fmoc groups. 0.2 mL of this solution was diluted to a total volume 
of 4.0 mL with acetonitrile in a quartz cuvette. The absorbance at 300 nm was recorded 
on a Cary 500 Scan UV-Vis-NIR Spectrophotometer. The extinction coefficient (ε) of 
Fmoc at 300 nm is 7040 M-1cm-1. Using Beer’s Law, for X g of resin with an absorbance 
of A, we can calculate the substitution level of Fmoc in the peptide chain by 
. This assay was done at chain length 9, 14, and 18 amino acids to 
€ 
SL(Fmoc) = 20 × A7040 × X
42	  
ensure that the solid phase peptide synthesizer was functioning correctly and that the 
synthesis was proceeding as expected. 
 
Table 2: Substitution levels  







After the addition of the final amino acid, lysine, the N-terminal Fmoc was 
removed following the above procedures, then the resin was washed 3 times with 20 mL 
of dichloroethane. Note that the N-terminus of this peptide was not acetylated. The 
peptide-resin was then dried overnight under vacuum. Meanwhile, 20 mL of the cleavage 
cocktail [95% trifluoroacetic acid (TFA), 2.5% H2O, 2.5% triisopropyl silane] was 
prepared. The cocktail was added to the dried peptide-resin, which turned dark red. This 
mixture was left at room temperature for 90 minutes and swirled occasionally. The resin 
was filtered out, and the light yellow filtrate containing the dissolved peptide was 
collected. This peptide solution was evaporated to an oil using a Buchi Rotovapor R-114 
rotary evaporator and Buchi Waterbath B-480 combination. This oil was then added drop 
wise to cold ethyl ether while stirring. The peptide precipitated as a white solid. The ethyl 
ether/ peptide mixture was stored in the freezer overnight to ensure full precipitation. 
Then the mixture was filtered to remove the solid peptide from the ether. The crude 
peptide was then dried under vacuum, and stored in a freezer. 
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Analytical HPLC of crude peptide 
 Analytical HPLC of the crude peptide was performed with a C-18 (VYDAC 
218TP104) reversed phase column and a flow rate of 1.5 mL/min. This was used to get a 
sense of what products resulted from the synthesis. Two solvents were used in this 
process: 
 Solvent A: 0.1% TFA in H2O 
 Solvent B: 0.1% TFA, 10% H2O, 90% Acetonitrile 
A 1 mg/mL solution of the crude peptide in 5% acetic acid, 0.1% TFA in H2O was 
prepared. This was injected 100 µL at a time into the column. The gradient profile was 
adjusted to optimize the program. The optimized analytical program was as follows: 
 
Table 3: Optimized analytical solvent program 
Time (m) Solvent A (%) Solvent B (%) 
0 85 15 
4 85 15 
44 78 22 
46 78 22 
48 0 100 
50 0 100 
52 85 15 
 
Preparative HPLC of Crude Peptide 
Preparative HPLC of the crude peptide was performed with a C-18 (Alltima 
250mm) reversed phase column and a flow rate of 7 mL/min. The program was 
optimized to isolate peak A and reduce run time. The same solvents were used for this 
process as for the analytical HPLC. A 20 mg/mL solution of the crude peptide in 5% 
acetic acid, 0.1% TFA in H2O was prepared. This was injected 100 µL at a time into the 
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column. The gradient profile was adjusted to optimize the program. The optimized 
preparative program was as follows: 
 
Table 4: Optimized preparative solvent program 
Time (m) Solvent A (%) Solvent B (%) 
0 80 20 
4 80 20 
22 76 24 
24 76 24 
26 0 100 
28 0 100 
30 80 20 
 
Isolation of Pure Peptide 
 The pure peptide was isolated from solution in two steps. First the HPLC eluant 
was spun on a Labconco centrivap concentrator with cold trap for approximately one 
hour to evaporate the acetonitrile. Then the aqueous solution was frozen in liquid 
nitrogen and put under vacuum on a Virtis Bechtop 3L Sentry lyophilizer to sublimate the 
water, leaving behind pure, dry peptide. This peptide was stored in a freezer to reduce 
degradation. 
 
MALDI-TOF Mass Spectroscopy 
 The matrix solution was made by combining 10 mg of α-cyano-4-hydroxy 
cinnamic acid with 500 µL acetonitrile and 500 µL 0.2% trifluoroacetic acid in H2O, 
mixing frequently over a 15-minute period to allow the crystals to dissolve. Only the 
clear supernatant was used in the next steps. Calibration standard and peptide solutions 
were prepared by dissolving 1 mg of sample in 62.5 µL acetonitrile and 62.5 µL 0.2% 
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TFA in H2O. The standard and peptide solutions were mixed with the matrix solution in a 
one to one ratio, and spotted on a Bruker MTP 394 target plate in 1 µL duplicate 
applications, and allowed to dry thoroughly.  The mass spectroscopy was then performed 
on a Bruker Autoflex Speed MALDI-TOF mass spectrometer.  
 
Circular Dichroism Spectroscopy 
 A 10 mM solution of 2-(4-morpholino)-ethane sulfonic acid buffer in deionized 
water was made and adjusted to pH 7 with 1 M NaOH. This buffer was mixed 50% v/v 
with 2,2,2-trifluoroethanol. Pure peptide was added to each solution at 1 mg/mL. The 
spectra were obtained on an Olis DSM CD spectrophotometer. Ellipticity was measured 
in triplicate at 1nm intervals from 195 nm-250 nm with an integration time of 60 seconds.  
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Appendix 1: MALDI-TOF Mass Spectroscopy of HPLC peak A 
53	  



















































Appendix 1: MALDI-TOF Mass Spectroscopy of HPLC peak C 
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